Bluebird Bio
FDA halts studies for bluebird bio’s sickle cell therapy LentiGlobin
February 24, 2021Research and Development Bluebird Bio, FDA, sickle cell disease
The FDA has put bluebird bio’s LentiGlobin gene therapy programme for sickle cell disease (SCD) on clinical hold, following Suspected …
Bluebird bio’s Lenti-D gene therapy shows promise in cerebral adrenoleukodystrophy
September 23, 2019Research and Development, Sales and Marketing Bluebird Bio, cerebral adrenoleukodystrophy, gene therapy, pharma
Bluebird bio has revealed updated data for its investigational Lenti-D gene therapy in the treatment of cerebral adrenoleukodystrophy (CALD), a …
EMA approves Bluebird Bio’s gene therapy Zynteglo
June 4, 2019Manufacturing and Production Bluebird Bio, European comission, gene therapy, health, pharma
The European Commission has granted a conditional marketing authorisation to bluebird bio’s gene therapy Zynteglo. The Massachusetts-based firm’s one time …
CHMP recommendation for bluebird bio’s gene therapy in β-thalassaemia
April 1, 2019Research and Development, Sales and Marketing Bluebird Bio, CHMP, EMA, Zynteglo, gene therapy, β-thalassaemia
Massachusetts-based bluebird bio has taken a significant leap forward in its pursuit of regulatory authorisation for its first gene therapy, …
Working Life: Nicola Redfern, UK General Manager, bluebird bio
February 28, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bluebird Bio, Interview, Working Life, pharma
How did you find your way into the pharma industry? Was it always an aspiration of yours? My mum worked …
bluebird bio reveals new UK General Manager
January 9, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bluebird Bio, appointment, pharma
bluebird bio, a US-based gene therapy biotech with a focus on cancer and severe genetic conditions, has named Nicola Redfern …
Medigene and bluebird bio expand immunotherapy partnership to $1.5bn
May 14, 2018Research and Development, Sales and Marketing Bluebird Bio, Cancer, Medigene, pharma
Medigene has announced that it has bolstered the existing partnership it has in place with US firm bluebird bio, originally …
bluebird backs own CAR-T prospect, takes option to co-develop with Celgene
March 29, 2018Sales and Marketing Bluebird Bio, CAR T, CAR-T, Celgene, biotech, drugs, pharma, pharmaceutical
Biotech companies showing faith in their own prospect drug candidates is not an unusual occurrence, some do it to extremes. …
Bluebird Bio gene therapy posts encouraging results in treatment of rare brain disease
April 21, 2016Medical Communications, Research and Development Bluebird Bio, Phase II, gene therapy, lenti-d, paediatric, phase 2, phase 3, phase III, rare brain disease
Bluebird bio (NASDAQ: BLUE) has announced positive interim data from a Phase II/III trial evaluating their Lenti-D gene therapy in …
Gene therapy advance hailed for thalassemia
September 16, 2010Research and Development Bluebird Bio, gene therapy, thalassemia
A new gene therapy for one of the most frequently inherited genetic disorders has produced promising results. The trial by …
